Jame Abraham, MD, discusses the results for the phase Ib study of trastuzumab emtansine with neratinib in patients with HER2-positive breast cancer.
Jame Abraham, MD, professor of medicine at the Cleveland Clinic and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses results from the phase Ib study of trastuzumab emtansine (T-DM1) with neratinib (Nerlynx) in patients with HER2-positive breast cancer.
The primary endpoint was to find a recommended phase II dose. For T-DM1, this dose was 3.6 mg/kg every 3 weeks, while the dose for neratinib was 160 mg daily, according to Abraham.
The FDA-approved dose of neratinib is 240 mg, but Abraham says the main side effect reported with this dose was diarrhea. Investigators saw response at 120 mg, 160 mg, and 200 mg, but the recommended dose of neratinib did not directly correlate with response.
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Peritoneal RFS May Be a Stronger Predictor of OS in CRC Peritoneal Metastasis
March 27th 2024In an interview with Targeted Oncology, Muhammad Talha Waheed, MBBS, discussed research on the reliability of using recurrence-free survival as an efficacy end point for trials evaluating patients with colorectal cancer peritoneal metastasis.
Read More
Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma
March 26th 2024Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed how the role of autologous stem cell transplant is evolving in the myeloma treatment landscape with the emergence of CAR T-cell therapies and bispecifics.
Read More